Oramed Pharma receives Investment Bank Analyst Rating Update
Investing.com - Oramed reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Oramed announced earnings per share...
Investing.com - Oramed reported on Wednesday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Oramed announced earnings per...
As it turns out, we’re not out of the woods yet in terms of the negative effects of the COVID-19 pandemic on the global economy. Last Monday, Goldman Sachs lowered its projections...
Endo International plc (NASDAQ:ENDP) swing trade is acting well and looks to me like it wants to get going. It popped 42 cents, or 9%, to 5.08, with a high of 5.15, on 9 million...
1. Axsome Therapeutics Inc (NASDAQ:AXSM) jumped 8.60, or 11%, to 89.57, just pennies off its high at 89.65, on 2.4 million shares on Wednesday. It has literally gone from the...
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
|Average||15.16 (+639.51% Upside)|
|No. of Analysts||5|